Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10

Ekatherine M. Prokopiou, Patricia A. Cooper, George Pettit, Michael C. Bibby, Shnyder D. Stevend

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Dolastatin 10, a marine natural product peptide, is now known to act as a vascular disrupting agent (VDA). These VDA properties were not known when other aspects of its promising pre-clinical profile led to initial unsuccessful clinical trials. Auristatin PYE, a synthetic analogue of dolastatin 10, has demonstrated improved activity in preliminary in vivo studies. However, as with other VDAs, tumour eradication was incomplete due to the maintenance of functional vasculature supporting the viable tumour at the periphery of the tumour xenograft, meaning that once the VDA effect subsides, the tumour regrows. One possible strategy for removing this peripheral tumour involves combining VDA therapy with another anticancer drug with a different mechanism of action. Here, we evaluated the effect of combining auristatin PYE with cisplatin in an HCT-116 human colon adenocarcinoma xenograft model. The effects on the growth of subcutaneously implanted HCT-116 xenografts in mice following intraperitoneal administration of a single dose of 4 mgkg-1 cisplatin and intravenous administration of 1 mgkg-1 auristatin PYE were evaluated compared to the effect of each agent administered alone. The effects on the functional tumour vasculature were also assessed. Statistically significant potentiation (p<0.01) was noted with a 465% growth delay for the combination group compared to the control, and 142 and 310% growth delays for the cisplatin and auristatin PYE groups, respectively. Shutdown of tumour vasculature in the combination group was similar to that observed with auristatin PYE on its own. Auristatin PYE demonstrated synergistic antitumour effects when combined with cisplatin, suggesting that a combination chemotherapy regimen would be the most effective strategy when applying this new anticancer drug.

Original languageEnglish (US)
Pages (from-to)309-313
Number of pages5
JournalMolecular Medicine Reports
Volume3
Issue number2
DOIs
StatePublished - Mar 2010

Fingerprint

dolastatin 10
Heterografts
Cisplatin
Tumors
Colon
Blood Vessels
Neoplasms
Growth
Chemotherapy
auristatin PYE
Combination Drug Therapy
Biological Products
Pharmaceutical Preparations
Intravenous Administration
Adenocarcinoma

Keywords

  • Auristatin PYE
  • Cisplatin
  • Colon adenocarcinoma
  • Combination therapy
  • Dolastatin 10
  • Pre-clinical
  • Tubulin-binder
  • Vascular disrupting agents

ASJC Scopus subject areas

  • Biochemistry
  • Cancer Research
  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Oncology

Cite this

Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10. / Prokopiou, Ekatherine M.; Cooper, Patricia A.; Pettit, George; Bibby, Michael C.; Stevend, Shnyder D.

In: Molecular Medicine Reports, Vol. 3, No. 2, 03.2010, p. 309-313.

Research output: Contribution to journalArticle

Prokopiou, Ekatherine M. ; Cooper, Patricia A. ; Pettit, George ; Bibby, Michael C. ; Stevend, Shnyder D. / Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10. In: Molecular Medicine Reports. 2010 ; Vol. 3, No. 2. pp. 309-313.
@article{d649f3bb7ec449a5857fcf4d2adc5812,
title = "Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10",
abstract = "Dolastatin 10, a marine natural product peptide, is now known to act as a vascular disrupting agent (VDA). These VDA properties were not known when other aspects of its promising pre-clinical profile led to initial unsuccessful clinical trials. Auristatin PYE, a synthetic analogue of dolastatin 10, has demonstrated improved activity in preliminary in vivo studies. However, as with other VDAs, tumour eradication was incomplete due to the maintenance of functional vasculature supporting the viable tumour at the periphery of the tumour xenograft, meaning that once the VDA effect subsides, the tumour regrows. One possible strategy for removing this peripheral tumour involves combining VDA therapy with another anticancer drug with a different mechanism of action. Here, we evaluated the effect of combining auristatin PYE with cisplatin in an HCT-116 human colon adenocarcinoma xenograft model. The effects on the growth of subcutaneously implanted HCT-116 xenografts in mice following intraperitoneal administration of a single dose of 4 mgkg-1 cisplatin and intravenous administration of 1 mgkg-1 auristatin PYE were evaluated compared to the effect of each agent administered alone. The effects on the functional tumour vasculature were also assessed. Statistically significant potentiation (p<0.01) was noted with a 465{\%} growth delay for the combination group compared to the control, and 142 and 310{\%} growth delays for the cisplatin and auristatin PYE groups, respectively. Shutdown of tumour vasculature in the combination group was similar to that observed with auristatin PYE on its own. Auristatin PYE demonstrated synergistic antitumour effects when combined with cisplatin, suggesting that a combination chemotherapy regimen would be the most effective strategy when applying this new anticancer drug.",
keywords = "Auristatin PYE, Cisplatin, Colon adenocarcinoma, Combination therapy, Dolastatin 10, Pre-clinical, Tubulin-binder, Vascular disrupting agents",
author = "Prokopiou, {Ekatherine M.} and Cooper, {Patricia A.} and George Pettit and Bibby, {Michael C.} and Stevend, {Shnyder D.}",
year = "2010",
month = "3",
doi = "10.3892/mmr-00000256",
language = "English (US)",
volume = "3",
pages = "309--313",
journal = "Molecular Medicine Reports",
issn = "1791-2997",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10

AU - Prokopiou, Ekatherine M.

AU - Cooper, Patricia A.

AU - Pettit, George

AU - Bibby, Michael C.

AU - Stevend, Shnyder D.

PY - 2010/3

Y1 - 2010/3

N2 - Dolastatin 10, a marine natural product peptide, is now known to act as a vascular disrupting agent (VDA). These VDA properties were not known when other aspects of its promising pre-clinical profile led to initial unsuccessful clinical trials. Auristatin PYE, a synthetic analogue of dolastatin 10, has demonstrated improved activity in preliminary in vivo studies. However, as with other VDAs, tumour eradication was incomplete due to the maintenance of functional vasculature supporting the viable tumour at the periphery of the tumour xenograft, meaning that once the VDA effect subsides, the tumour regrows. One possible strategy for removing this peripheral tumour involves combining VDA therapy with another anticancer drug with a different mechanism of action. Here, we evaluated the effect of combining auristatin PYE with cisplatin in an HCT-116 human colon adenocarcinoma xenograft model. The effects on the growth of subcutaneously implanted HCT-116 xenografts in mice following intraperitoneal administration of a single dose of 4 mgkg-1 cisplatin and intravenous administration of 1 mgkg-1 auristatin PYE were evaluated compared to the effect of each agent administered alone. The effects on the functional tumour vasculature were also assessed. Statistically significant potentiation (p<0.01) was noted with a 465% growth delay for the combination group compared to the control, and 142 and 310% growth delays for the cisplatin and auristatin PYE groups, respectively. Shutdown of tumour vasculature in the combination group was similar to that observed with auristatin PYE on its own. Auristatin PYE demonstrated synergistic antitumour effects when combined with cisplatin, suggesting that a combination chemotherapy regimen would be the most effective strategy when applying this new anticancer drug.

AB - Dolastatin 10, a marine natural product peptide, is now known to act as a vascular disrupting agent (VDA). These VDA properties were not known when other aspects of its promising pre-clinical profile led to initial unsuccessful clinical trials. Auristatin PYE, a synthetic analogue of dolastatin 10, has demonstrated improved activity in preliminary in vivo studies. However, as with other VDAs, tumour eradication was incomplete due to the maintenance of functional vasculature supporting the viable tumour at the periphery of the tumour xenograft, meaning that once the VDA effect subsides, the tumour regrows. One possible strategy for removing this peripheral tumour involves combining VDA therapy with another anticancer drug with a different mechanism of action. Here, we evaluated the effect of combining auristatin PYE with cisplatin in an HCT-116 human colon adenocarcinoma xenograft model. The effects on the growth of subcutaneously implanted HCT-116 xenografts in mice following intraperitoneal administration of a single dose of 4 mgkg-1 cisplatin and intravenous administration of 1 mgkg-1 auristatin PYE were evaluated compared to the effect of each agent administered alone. The effects on the functional tumour vasculature were also assessed. Statistically significant potentiation (p<0.01) was noted with a 465% growth delay for the combination group compared to the control, and 142 and 310% growth delays for the cisplatin and auristatin PYE groups, respectively. Shutdown of tumour vasculature in the combination group was similar to that observed with auristatin PYE on its own. Auristatin PYE demonstrated synergistic antitumour effects when combined with cisplatin, suggesting that a combination chemotherapy regimen would be the most effective strategy when applying this new anticancer drug.

KW - Auristatin PYE

KW - Cisplatin

KW - Colon adenocarcinoma

KW - Combination therapy

KW - Dolastatin 10

KW - Pre-clinical

KW - Tubulin-binder

KW - Vascular disrupting agents

UR - http://www.scopus.com/inward/record.url?scp=77950852374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950852374&partnerID=8YFLogxK

U2 - 10.3892/mmr-00000256

DO - 10.3892/mmr-00000256

M3 - Article

C2 - 21472238

AN - SCOPUS:77950852374

VL - 3

SP - 309

EP - 313

JO - Molecular Medicine Reports

JF - Molecular Medicine Reports

SN - 1791-2997

IS - 2

ER -